Contextual immersion trading strategy idea. Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The share price rose after announcing the availability of the CEO's 158-page book "Your COVID-19 Survival Manual: A Physician's Guide to Keep You and Your Family...
Contextual immersion trading strategy idea. The demand for shares of Atossa Therapeutics looks higher than the supply. The company develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions. Due to the spread of COVID-19, the demand for the company`s services rose. This and other conditions can cause a rise in...
ATOS Short Term Prediction. Spotted Cup & Handle for ATOS. The RSI dipped below 50 with MACD histogram showing good progress of moving towards the 0 line. Entry in the 1.50’s is a good buy before it jumps above 2$ within a week or two.
ATOS: Atossa Genetics Inc. 2019-12-19 08:30:10 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
About Atossa Genetics Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density This is what we are looking for, go long with this CV company. Find a good entry point and squat!! If FDA approved this will go back where it cam from $$$
The rumor mill continues to spin in ATOS prior to a presentation scheduled for April the 25th, the spike in volume hopefully preempts a positive move. Keep it on the watchlist.
Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, yesterday FDA Aprroved Oral Endoxifen for breast cancer patient. Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to prevent new as well as recurrent disease in breast...
$10 target is picked because thats where 200 SMA is at.
ATOS is making a double bottom and is about to break out soon.
look for a long after breaking of trend and pull back to the level it broke up, if this level holds should be good indication of going up to the next levels.
Don't have time to lay out the details. Recent squeeze, warrants didnt get exercised either. Chance that this next squeeze will follow through with an offering SHORT TERM TRADE
Yesturday marked a possible buy signal. The price action is making newer lows, while the MACD is making higher highs, this marks a bullish divergence. Tomorrow should be the confirmation of this signal, if and only if this it closes higher than todays close.